| Company/Division name | Forge Biologics with Labcorp |
| Parent company | Forge Biologics with Labcorp |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| City reshored to: | Columbus |
| State(s) reshored to: | OH |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | adeno-associated virus (AAV) mediated gene therapy |
| What domestic positive factors made reshoring more attractive? | Better Control of Process/Delivery/Factory, Customization/Flexibility, Eco-system synergies, Higher productivity, Infrastructure, Lead time/Time to market, Lean/other business process improvement techniques, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
